scholarly journals Anticoccidial Activity of Aloe debrana and Aloe pulcherrima Leaf Gel against Eimeria Oocysts

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Andualem Yimer Desalegn ◽  
Mulubrihan Rahimeto Ahmed
Keyword(s):  
Infectious Diseases ◽  
Potassium Dichromate ◽  
Potassium Dichromate Solution ◽  
Control Groups ◽  
Development Of Resistance ◽  
Frequent Use ◽  
Huge Impact ◽  
Anticoccidial Activity ◽  
Avian Coccidiosis

Avian coccidiosis is one of the serious infectious diseases that pose huge impact on the health and production of poultry, hence mainly controlled by regular use of prophylactic and therapeutic chemical drugs. Frequent use of anticoccidial drugs, however, has resulted in the development of resistance in the Eimeria species and concerns about drug residues which have stimulated the efforts to search for alternative. Aloe pulcherrima and Aloe debrana are some of the endemic Aloe species of Ethiopia which are traditionally used for the treatment of various infectious diseases. In this study, an in vitro trial was undertaken to evaluate the effect of Aloe debrana and A. pulcherrima leaf gel infusions on the inhibition of the sporulation of oocysts of mixed Eimeria species isolated from naturally infected chickens. In this assay, petri dishes containing unsporulated coccidian oocysts at a dose of 1500 oocysts/ml of fecal solution were randomly assigned to 10, 15, 25, and 30% w/v crude gel infusion of both aloe species in 1% potassium dichromate solution while Amprolium and distilled water served as control groups. The results of this study show that 10, 15, 25, and 3 0% w/v gel infusions at the tested concentrations have anticoccidial activity as evidenced by their ability to decrease significantly (P<0.05) the sporulation of Eimeria oocysts relative to the control incubation. The efficacy of A. debrana was found significantly better (P<0.05) than A. pulcherrima at different concentrations. However, A. debrana at 30% concentration showed significantly higher (P<0.05) sporulation inhibition efficacy of 79.35% (CI: 75.99-83.21) compared to A. pulcherrima (69.17%, CI: 64.65-73.92) at similar concentration in relation to the control incubation, though this could not be compared to Amprolium which was more effective (P<0.05) with an inhibition percentage of 90.54% (CI: 89.16-92.21). This study has shown that there is potential for use of Aloe debrana leaf gel for the control of avian coccidiosis and as a chemotherapeutic, though much research is needed to determine absolute concentration which will make it comparable to commercially available drugs in terms of efficacy.

scholarly journals In vitro anticoccidial activity of Vitis vinifera extract on oocysts of different Eimeria species of Broiler Chicken

2020 ◽  
Vol 71 (3) ◽  
pp. 2267
Author(s):  
R.Z. ABBAS ◽  
A. ABBAS ◽  
Z. IQBAL ◽  
M.A. RAZA ◽  
K. HUSSAIN ◽  
...  
Keyword(s):  
Vitis Vinifera ◽  
Potassium Dichromate ◽  
Eimeria Species ◽  
Grape Seed ◽  
Inhibitory Effect ◽  
Potassium Dichromate Solution ◽  
Dependent Manner ◽  
Control Groups ◽  
Dose Dependent

In the current experiment, the in vitro anticoccidial effect of Vitis venifera (grape seed) extract was evaluated. For this purpose, an in vitro sporulation inhbition assay was used. Collected oocysts of four Eimeria species (E. tenella, E. necatrix, E. brunetti and E. mitis) were exposed to six different concentrations (w/v) of Vitis vinifera extract (VVE) in 10% Dimethylsulphoxide solution (DMSO), while Dimethylsulphoxide (DMSO) and Potassium dichromate solution (K2Cr2O7) served as control groups. The results of the present study revealed that V. vinifera extract showed inhibitory effect on sporulation (%) and damage (%) of Eimeria oocysts in a dose dependent manner as compared to both control groups. V. vinifera extract also damaged the morhology of oocysts in terms of shape, size and number of sporocysts.

Resistance of faecal cysts of Spironucleus muris to some physical factors and chemical substances

1978 ◽  
Vol 12 (2) ◽  
pp. 95-97 ◽  
Author(s):  
I. Kunstýy̌ ◽  
E. Ammerpohl
Keyword(s):  
Osmotic Pressure ◽  
Chloride Solution ◽  
Room Temperature ◽  
Potassium Dichromate ◽  
Low Ph ◽  
Potassium Dichromate Solution ◽  
Physical Factors ◽  
High And Low Temperatures

The effect of 5 disinfectants, and of saturated zinc chloride solution + sodium chloride solution, 2·5% potassium dichromate solution, and 0·12% dimetridazole on faecal cysts of Spironuc1eus muris were tested in vitro. The resistance of the cysts to high and low temperatures, low pH, high osmotic pressure, centrifugation and desiccation was also tested. After treatment the morphology of the cysts was observed microscopically and their infectivity tested in vivo on sensitive thymus-deficient nude mice. The cysts ceased to be infective after treatment with most of usual distinfectants and by high temperature (45°C for 30 min). They resisted 0·12% dimetridazole, low temperature (-196°C), low pH (2·2), high osmotic pressure (distilled water and 30% 'Ficoll'), centrifugation (1500 g/20 min) and desiccation (room temperature for 14 days). These data may be useful for the control of Spironuc1eus muris infection in rodents and for cryopreservation of the parasite for experimental purposes.

scholarly journals Preliminary screening of the possible protective effect of Moroccan propolis against chromium-induced nephrotoxicity in animal model

2020 ◽  
Vol 13 (7) ◽  
pp. 1327-1333
Author(s):  
Soukaina El-Guendouz ◽  
Soumia Zizi ◽  
Youssef Elamine ◽  
Badiaa Lyoussi
Keyword(s):  
Animal Model ◽  
Protective Effect ◽  
Creatinine Clearance ◽  
Potassium Dichromate ◽  
Treated Group ◽  
Control Groups ◽  
Before And After ◽  
And Control

Background and Aim: Hexavalent chromium (Cr (VI)) compounds have been shown to induce nephrotoxicity associated with oxidative stress in humans and animals. The aim of the present study was to investigate the nephroprotective effect of bee propolis, as highly antioxidant natural product, in vivo using an animal model. Materials and Methods: First of all, total phenol and flavonoid contents of propolis sample were estimated in vitro. Afterward, to study the protective effect of propolis on renal damages caused by an injection of a single dose of potassium dichromate (15 mg/kg b.wt), 24 male Wister rats were divided into test and control groups. Propolis treatment was performed by oral gavage of 100 mg/kg b.wt/day, while the control groups received water instead. The 24 h urine was collected and blood samples were withdrawn before and after each treatment for further analysis. Results: Propolis revealed to be rich in polyphenols and flavonoids. Chromate provoked a nephrotoxic effect expressed by a drastic decrease in glomerular filtration assessed by creatinine clearance. However, the administration of propolis attenuated the renal damages induced by the chromate. This attenuation can be seen by the increase of creatinine clearance when comparing propolis treated group to the non-treated group. Conclusion: Propolis showed a protective potential against chromate-induced nephrotoxicity through the amelioration of chromate's toxic effects. It might be concluded that propolis could be effective as chemoprotectant in the management of potassium dichromate-induced nephrotoxicity.

THE IN VITRO HATCHING OF ASCARIS LUMBRICOIDES EGGS

1961 ◽  
Vol 39 (2) ◽  
pp. 153-162 ◽  
Author(s):  
Donald Fairbairn
Keyword(s):  
Ascaris Lumbricoides ◽  
Morphological Changes ◽  
Potassium Dichromate ◽  
Vitelline Membrane ◽  
Potassium Dichromate Solution ◽  
Sodium Bisulphite ◽  
Reducing Conditions ◽  
Low Degree ◽  
First Results

The stimulus leading to in vitro hatching of Ascaris lumbricoides eggs consisted of four components as follows: (1) a temperature similar to that of homoiothermic animals, (2) pCO2 approximating 5 vol.%, (3) pH near 7.0, (4) non-specific reducing conditions such as are established by cysteine, glutathione, sodium hydrosulphite, sodium bisulphite, or sulphur dioxide. Application of this stimulus resulted in 80–95% hatching in 3 hours, the observed morphological changes corresponding to those occurring during intestinal hatching. The stimulus was not effective when applied to preinfective stages of embryonic development, or to infective eggs which were embryonated in 2% potassium dichromate solution. Maximal hatching was obtained when the stimulus was applied continuously. One of the first results of stimulation may be increased permeability of the vitelline membrane sufficient to permit the outward passage of enzymes such as chitinase which digest the chitinous shell. There is no reason to believe that the in vitro stimulus differs significantly from the natural stimulus, which is common to many homoiothermic animals and may account in part for the low degree of host-specificity in Ascaris infections.

Mechanisms involved in effects of antimicrobial peptides, bactenectins ChBac3.4, ChBac5, and mini-ChBac7.5Nb, on bacterial cells

2017 ◽  
pp. 43-50
Author(s):  
О.В. Шамова ◽  
М.С. Жаркова ◽  
П.М. Копейкин ◽  
Д.С. Орлов ◽  
Е.А. Корнева
Keyword(s):  
Escherichia Coli ◽  
Antimicrobial Activity ◽  
Innate Immunity ◽  
Infectious Diseases ◽  
Metabolic Activity ◽  
Capra Hircus ◽  
Bacterial Cells ◽  
Antibiotic Resistant ◽  
Resistant Strains

Антимикробные пептиды (АМП) системы врожденного иммунитета - соединения, играющие важную роль в патогенезе инфекционных заболеваний, так как обладают свойством инактивировать широкий спектр патогенных бактерий, обеспечивая противомикробную защиту живых организмов. В настоящее время АМП рассматриваются как потенциальные соединения-корректоры инфекционной патологии, вызываемой антибиотикорезистентными бактериями (АБР). Цель данной работы состояла в изученим механизмов антибактериального действия трех пептидов, принадлежащих к семейству бактенецинов - ChBac3.4, ChBac5 и mini-ChBac7.5Nb. Эти химически синтезированные пептиды являются аналогами природных пролин-богатых АМП, обнаруженных в лейкоцитах домашней козы Capra hircus и проявляющих высокую антимикробную активность, в том числе и в отношении грамотрицательных АБР. Методы. Минимальные ингибирующие и минимальные бактерицидные концентрации пептидов (МИК и МБК) определяли методом серийных разведений в жидкой питательной среде с последующим высевом на плотную питательную среду. Эффекты пептидов на проницаемость цитоплазматической мембраны бактерий для хромогенного маркера исследовали с использованием генетически модифицированного штамма Escherichia coli ML35p. Действие бактенецинов на метаболическую активность бактерий изучали с применением маркера резазурина. Результаты. Показано, что все исследованные пептиды проявляют высокую антимикробную активность в отношении Escherichia coli ML35p и антибиотикоустойчивых штаммов Escherichia coli ESBL и Acinetobacter baumannii in vitro, но их действие на бактериальные клетки разное. Использован комплекс методик, позволяющих наблюдать в режиме реального времени динамику действия бактенецинов в различных концентрациях (включая их МИК и МБК) на барьерную функцию цитоплазматической мембраны и на интенсивность метаболизма бактериальных клеток, что дало возможность выявить различия в характере воздействия бактенецинов, отличающихся по структуре молекулы, на исследуемые микроорганизмы. Установлено, что действие каждого из трех исследованных бактенецинов в бактерицидных концентрациях отличается по эффективности нарушения целостности бактериальных мембран и в скорости подавления метаболизма клеток. Заключение. Полученная информация дополнит существующие фундаментальные представления о механизмах действия пролин-богатых пептидов врожденного иммунитета, а также послужит основой для биотехнологических исследований, направленных на разработку на базе этих соединений новых антибиотических препаратов для коррекции инфекционных заболеваний, вызываемых АБР и являющимися причинами тяжелых внутрибольничных инфекций. Antimicrobial peptides (AMPs) of the innate immunity are compounds that play an important role in pathogenesis of infectious diseases due to their ability to inactivate a broad array of pathogenic bacteria, thereby providing anti-microbial host defense. AMPs are currently considered promising compounds for treatment of infectious diseases caused by antibiotic-resistant bacteria. The aim of this study was to investigate molecular mechanisms of the antibacterial action of three peptides from the bactenecin family, ChBac3.4, ChBac5, and mini-ChBac7.5Nb. These chemically synthesized peptides are analogues of natural proline-rich AMPs previously discovered by the authors of the present study in leukocytes of the domestic goat, Capra hircus. These peptides exhibit a high antimicrobial activity, in particular, against antibiotic-resistant gram-negative bacteria. Methods. Minimum inhibitory and minimum bactericidal concentrations of the peptides (MIC and MBC) were determined using the broth microdilution assay followed by subculturing on agar plates. Effects of the AMPs on bacterial cytoplasmic membrane permeability for a chromogenic marker were explored using a genetically modified strain, Escherichia coli ML35p. The effect of bactenecins on bacterial metabolic activity was studied using a resazurin marker. Results. All the studied peptides showed a high in vitro antimicrobial activity against Escherichia coli ML35p and antibiotic-resistant strains, Escherichia coli ESBL and Acinetobacter baumannii, but differed in features of their action on bacterial cells. The used combination of techniques allowed the real-time monitoring of effects of bactenecin at different concentrations (including their MIC and MBC) on the cell membrane barrier function and metabolic activity of bacteria. The differences in effects of these three structurally different bactenecins on the studied microorganisms implied that these peptides at bactericidal concentrations differed in their capability for disintegrating bacterial cell membranes and rate of inhibiting bacterial metabolism. Conclusion. The obtained information will supplement the existing basic concepts on mechanisms involved in effects of proline-rich peptides of the innate immunity. This information will also stimulate biotechnological research aimed at development of new antibiotics for treatment of infectious diseases, such as severe in-hospital infections, caused by antibiotic-resistant strains.

Current Challenges in the Development of Vaccines and Drugs Against Emerging Vector-borne Diseases

2019 ◽  
Vol 26 (16) ◽  
pp. 2974-2986 ◽  
Author(s):  
Kwang-sun Kim
Keyword(s):  
New Host ◽  
In Vivo Models ◽  
Vector Borne Diseases ◽  
Novel Drugs ◽  
Huge Impact ◽  
Tick Borne Disease ◽  
Vector Borne ◽  
Living Organisms

Vectors are living organisms that transmit infectious diseases from an infected animal to humans or another animal. Biological vectors such as mosquitoes, ticks, and sand flies carry pathogens that multiply within their bodies prior to delivery to a new host. The increased prevalence of Vector-Borne Diseases (VBDs) such as Aedes-borne dengue, Chikungunya (CHIKV), Zika (ZIKV), malaria, Tick-Borne Disease (TBD), and scrub typhus has a huge impact on the health of both humans and livestock worldwide. In particular, zoonotic diseases transmitted by mosquitoes and ticks place a considerable burden on public health. Vaccines, drugs, and vector control methods have been developed to prevent and treat VBDs and have prevented millions of deaths. However, development of such strategies is falling behind the rapid emergence of VBDs. Therefore, a comprehensive approach to fighting VBDs must be considered immediately. In this review, I focus on the challenges posed by emerging outbreaks of VBDs and discuss available drugs and vaccines designed to overcome this burden. Research into promising drugs needs to be upgraded and fast-tracked, and novel drugs or vaccines being tested in in vitro and in vivo models need to be moved into human clinical trials. Active preventive tactics, as well as new and upgraded diagnostics, surveillance, treatments, and vaccination strategies, need to be monitored constantly if we are to manage VBDs of medical importance.

scholarly journals International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases

2011 ◽  
Vol 52 (5) ◽  
pp. e103-e120 ◽  
Author(s):  
Kalpana Gupta ◽  
Thomas M. Hooton ◽  
Kurt G. Naber ◽  
Björn Wullt ◽  
Richard Colgan ◽  
...  
Keyword(s):  
Infectious Diseases ◽  
European Society ◽  
Uncomplicated Urinary Tract Infection ◽  
Collateral Damage ◽  
Medical Microbiology ◽  
Acute Uncomplicated Cystitis ◽  
American Urological Association ◽  
Uncomplicated Cystitis ◽  
International Experts

Abstract A Panel of International Experts was convened by the Infectious Diseases Society of America (IDSA) in collaboration with the European Society for Microbiology and Infectious Diseases (ESCMID) to update the 1999 Uncomplicated Urinary Tract Infection Guidelines by the IDSA. Co-sponsoring organizations include the American Congress of Obstetricians and Gynecologists, American Urological Association, Association of Medical Microbiology and Infectious Diseases–Canada, and the Society for Academic Emergency Medicine. The focus of this work is treatment of women with acute uncomplicated cystitis and pyelonephritis, diagnoses limited in these guidelines to premenopausal, non-pregnant women with no known urological abnormalities or co-morbidities. The issues of in vitro resistance prevalence and the ecological adverse effects of antimicrobial therapy (collateral damage) were considered as important factors in making optimal treatment choices and thus are reflected in the rankings of recommendations.

scholarly journals 1592. Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa With Overexpression of AmpC β-Lactamase From Phase 3 Clinical Trials

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S792-S793
Author(s):  
Lynn-Yao Lin ◽  
Dmitri Debabov ◽  
William Chang ◽  
Urania Rappo
Keyword(s):  
Clinical Trials ◽  
Active Agent ◽  
Complicated Urinary Tract Infection ◽  
Carbapenem Resistance ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Control Groups ◽  
In Vitro Susceptibility ◽  
Intra Abdominal Infection

Abstract Background AmpC overproduction is a main mechanism of carbapenem resistance, in the absence of acquired carbapenemases. Ceftazidime-avibactam (CAZ-AVI) has potent in vitro activity against AmpC-producing P. aeruginosa and Enterobacterales that are resistant to carbapenems and other β-lactams. Methods Activity of CAZ-AVI and comparators was evaluated against AmpC-overproducing Enterobacterales (n=77) and P. aeruginosa (n=53) collected from 4 CAZ-AVI clinical trials: RECLAIM (complicated intra-abdominal infection [cIAI]), REPRISE (cIAI/complicated urinary tract infection [cUTI]), RECAPTURE (cUTI) and REPROVE (hospital-acquired pneumonia/ventilator associated pneumonia). In vitro susceptibility of CAZ-AVI and comparators was performed by broth microdilution using ThermoFisher custom panels. CLSI breakpoints were used to determine susceptibility. Quantitative PCR and microarray data were used to characterize presence and expression of AmpC. Clinical response at test of cure was assessed. Results Against 77 AmpC-overproducing Enterobacterales isolates, meropenem-vaborbactam (MVB) (98.7% susceptible [S]), CAZ-AVI (96.1% S), and meropenem (MEM) (96.1% S) had similar in vitro activity (Table), with greater in vitro activity than amikacin (AMK) (84.4% S), gentamicin (61.0% S), and ceftolozane-tazobactam (TZC) (35.1% S). Clinical cures in patients with baseline AmpC-overproducing Enterobacterales were 21/26 (81%) in CAZ-AVI group vs 17/20 (85%) in control groups. Against 53 AmpC-overproducing P. aeruginosa isolates, CAZ-AVI (73.6% S) showed greater in vitro activity than AMK (69.8% S), TZC (58.5% S), and MEM (37.7% S). Clinical cures in patients with baseline AmpC-overproducing P. aeruginosa were 12/14 (86%) in CAZ-AVI group vs 9/12 (75%) in control groups. MIC distributions against the same P aeruginosa isolates were CAZ-AVI (MIC50/90, 4/ &gt;64 µg/mL), MVB (MIC50/90, 8/32 µg/mL), and MEM (MIC50/90, 8/32 µg/mL). Table Conclusion CAZ-AVI was the most active agent against AmpC-overproducing P. aeruginosa with higher proportion of clinical cure than controls. CAZ-AVI was also among the most active agents against AmpC-overproducing Enterobacterales, with &gt;96% isolates susceptible. Disclosures Lynn-Yao Lin, MS, AbbVie (Employee) Dmitri Debabov, PhD, AbbVie (Employee) William Chang, BS, AbbVie (Employee) Urania Rappo, MD, MS, PharmD, Allergan (before its acquisition by AbbVie) (Employee)

scholarly journals Application of 3D bioprinting in the prevention and the therapy for human diseases

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Hee-Gyeong Yi ◽  
Hyeonji Kim ◽  
Junyoung Kwon ◽  
Yeong-Jin Choi ◽  
Jinah Jang ◽  
...  
Keyword(s):  
Infectious Disease ◽  
Infectious Diseases ◽  
Rapid Development ◽  
In Vitro Models ◽  
Delivery Systems ◽  
Advanced Technology ◽  
3D Bioprinting ◽  
Disease Research ◽  
Infectious Disease Research

AbstractRapid development of vaccines and therapeutics is necessary to tackle the emergence of new pathogens and infectious diseases. To speed up the drug discovery process, the conventional development pipeline can be retooled by introducing advanced in vitro models as alternatives to conventional infectious disease models and by employing advanced technology for the production of medicine and cell/drug delivery systems. In this regard, layer-by-layer construction with a 3D bioprinting system or other technologies provides a beneficial method for developing highly biomimetic and reliable in vitro models for infectious disease research. In addition, the high flexibility and versatility of 3D bioprinting offer advantages in the effective production of vaccines, therapeutics, and relevant delivery systems. Herein, we discuss the potential of 3D bioprinting technologies for the control of infectious diseases. We also suggest that 3D bioprinting in infectious disease research and drug development could be a significant platform technology for the rapid and automated production of tissue/organ models and medicines in the near future.

Supplementation of c-type natriuretic peptide during in vitro growth period benefits the development of murine preantral follicles

Zygote ◽  
2020 ◽  
pp. 1-5
Author(s):  
Li Ang ◽  
Cao Haixia ◽  
Li Hongxia ◽  
Li Ruijiao ◽  
Guo Xingping ◽  
...  
Keyword(s):  
Natriuretic Peptide ◽  
Granulosa Cells ◽  
Culture System ◽  
Early Stage ◽  
Developmental Competence ◽  
Control Group ◽  
Follicle Development ◽  
Control Groups ◽  
Preantral Follicles

Summary The present study investigated the effects of c-type natriuretic peptide (CNP) on the development of murine preantral follicles during in vitro growth (IVG). Preantral follicles isolated from ovaries of Kunming mice were cultured in vitro. In the culture system, CNP was supplemented in the experimental groups and omitted in the control groups. In Experiment 1, CNP was only supplemented at the early stage and follicle development was evaluated. In Experiments 2 and 3, CNP was supplemented during the whole period of in vitro culture. In Experiment 2, follicle development and oocyte maturity were evaluated. In Experiment 3, follicle development and embryo cleavage after in vitro fertilization (IVF) were assessed. The results showed that in the control groups in all three experiments, granulosa cells migrated from within the follicle and the follicles could not reach the antral stage. In the experimental groups in all three experiments, no migration of granulosa cells was observed and follicle development was assessed as attaining the antral stage, which was significantly superior to that of the control group (P < 0.0001). Oocyte meiotic arrest was effectively maintained, hence giving good developmental competence. In conclusion, CNP supplementation in the culture system during IVG benefited the development of murine preantral follicles.

Sign in / Sign up

Export Citation Format

Share Document